# Remedicine CO.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remedicine-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.remd.cn
- Total disclosed funding: $30M
- Latest round: Series A (Feb 17, 2023)
- Investors on record: 3

## About

Established in 2016 and based in Shanghai, China, Remedicine CO., LTD operate as a tumor treatment equipment developer that focuses on the irreversible electroporation field.  It has completed 3 rounds of funding as of 2023.  In July 2022, its pulsed electric field ablation device was also approved by the State Drug Administration of China and entered the special review process for innovative medical devices.

The company provides tumor treatment equipment for the irreversible electroporation fields.  The product of the company includes compound steep pulse treatment equipment.  The business of the company includes the research and development, production, and sales of medical devices, and technical consulting and services.  The company adopts irreversible electroporation technology.

The company will use the series A+ funding to accelerate the layout and innovation of its products in prostate enlargement, PFA (electrophysiological atrial fibrillation), liver cancer, and other areas.

## Funding rounds

- Series A, Feb 17, 2023, $15M — Detong Capital, TTGG Ventures, Zhejiang Qianzhan Investment Management
- Series A, Sep 1, 2021, $16M — Detong Capital

## Investors

- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series A
- Zhejiang Qianzhan Investment Management (https://capitalatlas.ai/funds/zhejiang-qianzhan-investment-management) — Series A